A Study of LY3314814 in Participants With Mild Alzheimer's Disease Dementia (DAYBREAK-ALZ)

What is the purpose of this trial?

Visit the Alzheimer's Disease Research Unit (ADRU) here.

The main purpose of this study is to evaluate the efficacy of the study drug known as LY3314814 in participants with mild Alzheimer's disease (AD) dementia.


Participation Guidelines

Ages: 55 - 85 years

Gender: Both


Eli Lilly and Company

Start Date: 11/02/2016

End Date: 08/31/2019

Last Updated: 02/22/2018

Study HIC#: 1605017755

Get Involved

For more information about this study, contact:
Emily C Kemp
+1 203-764-8100
emily.kemp@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Christopher H Van Dyck

Principal Investigator

Sub-Investigators